section name header

Evidence summaries

Somatostatin, Octreotide and Gabexate Mesilate for Acute Pancreatitis

Antisecretory agents (somatostatin and octreotide) reduce mortality in severe acute pancreatitis. Level of evidence: "A"

A systematic review 1 including 12 studies on somatostatin (n=703), 9 studies on octreotide (n=948), and 8 studies on gabexate mesilate (n=896) was abstracted in DARE. All studies were controlled clinical trials (randomised or non-randomised). In severe acute pancreatitis, both somatostatin (OR 0.36, 95% CI 0.20 to 0.64) and octreotide (OR 0.57, 95% CI 0.35 to 0.88) were beneficial in improving overall mortality. Gabexate mesialate had no effect on mortality but improved complication rate.

    References

    • Andriulli A, Leandro G, Clemente R, Festa V, Caruso N, Annese V, Lezzi G, Lichino E, Bruno F, Perri F. Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Aliment Pharmacol Ther 1998 Mar;12(3):237-45. [PubMed] [DARE]

Primary/Secondary Keywords